Skip to main content

Viatris Inc Value Stock - Dividend - Research Selection

Viatris

ISIN: US92556V1061 , WKN: A2QAME

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


44th Annual J.P. Morgan Healthcare Conference

2026-01-13
2026-01-13. The following slide deck was published by Viatris Inc.

Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2026-01-13
Viatris Inc. (VTRS) 44th Annual J.P.

Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target

2026-01-09
The recent update to Viatris centers on a refreshed US$16 price target, set against a fair value estimate that has inched from about US$12.44 to roughly US$12.67 as the affordable medicines theme gains attention. Analysts tying the higher target to this theme are effectively saying the model now gives slightly more credit to Viatris’ ability to fit ongoing demand for cost conscious healthcare options as 2026 approaches. Continue reading this article to see how you can keep on top of these...

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer

2026-01-08
Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.

1 Stock Under $50 Worth Your Attention and 2 That Underwhelm

2026-01-08
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

ADPV: Market Timing ETF With High Fees And Average Results

2026-01-07
High turnover, a 1% expense ratio, a short track record, and unconvincing performance raise concerns for the Adaptiv™ Select ETF. Read the full analysis here.

Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock?

2026-01-06
Viatris (VTRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 Healthcare Stock to Target This Week and 2 We Turn Down

2026-01-06
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 17.2% over the past six months, topping the S&P 500 by 7.1 percentage points.

A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones

2026-01-05
Viatris (VTRS) shares are back in focus after the company reported four regulatory milestones, including US FDA approval for a generic octreotide acetate injectable and progress on contraceptive, gene therapy, and sleep-disorder treatments. See our latest analysis for Viatris. These pipeline updates arrive as Viatris shares trade at $12.46, with a 30 day share price return of 14.0% and a 90 day share price return of 22.88%, while the 1 year total shareholder return is 9.57% and the 3 year...

Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones

2026-01-02
Viatris Inc. (NASDAQ:VTRS) is one of the top cheap stocks under $20 to buy now. On December 18, Viatris Inc. (NASDAQ:VTRS) announced four recent regulatory milestones spread across all stages of the company’s global pipeline. It stated that the FDA approved the company’s octreotide acetate for injectable suspension, which is a generic version of Sandostatin® […]